论文部分内容阅读
食道静脉曲张破裂所致的出血是肝硬化最严重的并发症,可导致患这种并发症的1/3病人死亡,同时也是1/3肝硬化患者死亡的原因。β-阻滞剂可使首次出血的食道静脉曲张患者再出血的危险性降低约50％。目前主张对有肝硬化且有出血危险的静脉曲张患者使用β-阻滞剂。然而,β-阻滞剂的疗效还是不尽如人意的。治疗无效的一个可能原因是门静脉压降得不够充分。本文报告服用单硝酸异山梨酯作为β-阻滞剂纳多洛尔的辅助药物在预防肝硬化患者静脉曲张首次破裂出血中的试验结果。 从1991年12月至1994年2月在意大利的9个医疗
Bleeding due to rupture of esophageal varices is the most serious complication of cirrhosis and can lead to 1 in 3 patient deaths and 1 in 3 cirrhosis. Beta-blockers reduce the risk of rebleeding in first bleeding patients with esophageal varices by about 50%. Currently advocated the use of beta blockers in patients with cirrhosis and bleeding risk of varicose veins. However, the efficacy of beta-blockers is still not satisfactory. One possible reason for the ineffective treatment is inadequate portal pressure drop. This article reports the use of isosorbide mononitrate as a beta-blocker nadolol adjunct to prevent cirrhosis patients with variceal hemorrhage in the first test results. Nine medical treatments in Italy from December 1991 to February 1994